The case involves a section of the patent law in India that is designed to prevent companies from receiving new patents by making minor changes to existing drugs, unless those changes significantly improve the effectiveness of the drug. One question at issue is whether the criteria used to determine significant improvement are sufficiently defined.
A concern of both the Pharmaceutical Research and Manufacturers of America and the US government is that unless the current law is challenged, it may lead to similar vague standards in other countries.
